OncoMatch/Clinical Trials/NCT06957327
A Study of ERAS-601 in People With Chordoma
Is NCT06957327 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ERAS-601 for chordoma.
Treatment: ERAS-601 — The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Excluded: PTPN11 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: SHP2 inhibitor
Previous treatment with a SHP2 inhibitor
Cannot have received: antineoplastic therapy
Exception: within <21 days or 5 half-lives, whichever is shorter
Patients with prior antineoplastic therapy within <21 days or 5 half-lives, whichever is shorter
Cannot have received: radiation therapy
Exception: within 14 days of Cycle 1, Day 1
Received radiation within 14 days of Cycle 1, Day 1
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5 x 10^3/mL; Platelet count ≥ 75 × 10^3/mL without symptomatic bleeding; Hemoglobin > 9 g/dL
Kidney function
Serum creatinine clearance <1.5 times ULN or ≥ 50 mL/min as determined by Cockcroft-Gault (creatinine clearance need not be calculated if serum creatinine is within normal limits)
Liver function
AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases; Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
Screening laboratory values must meet the following criteria: ANC ≥ 1.5 x 10^3/mL; Platelet count ≥ 75 × 10^3/mL without symptomatic bleeding; Hemoglobin > 9 g/dL; Serum electrolytes (sodium, potassium, magnesium, phosphorus, calcium) Grade ≤1 or within the institutional ranges of normal. If clinically appropriate, electrolytes may be corrected, and values reassessed prior to enrollment. AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases; Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL); Serum creatinine clearance <1.5 times ULN or ≥ 50 mL/min as determined by Cockcroft-Gault (creatinine clearance need not be calculated if serum creatinine is within normal limits).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify